Preparing for the Unitary Patent
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Preparing for the Unitary Patent

Sponsored by

inspicos-400px.png
christian-lue-8yw6tsb8tnc-unsplash.jpg

Jakob Pade Frederiksen of Inspicos P/S discusses the Unitary Patent and Unified Patent Court regime expected to enter into force by early 2023

The Unitary Patent (UP) and Unified Patent Court (UPC) regime is expected to enter into force in late 2022 or early 2023. Under the future system, patentees may request unitary effect for their patents in the 17 EU States currently participating to the system. Patents with unitary effect will not have to undergo country-by-country validation. 

The exact date of entry into force of the new system will be triggered by Germany’s depositing of its instrument of ratification of the Unified Patent Court Agreement. 

In preparation for the coming into existence of the new system, the EPO has implemented transitional measures applicable to European patent applications having reached the final stage of the grant proceedings. 

The measures will be available for European patent applications, in respect of which the EPO has issued its communication under Rule 71(3) EPC informing the applicant of the intention to grant a patent. 

The first transitional measure provides the possibility for applicants to file a request for unitary effect before the entry into force of the new system. Once the UP system has started, the EPO will register unitary effect. Requests for unitary effect cannot, however, be validly filed before Germany deposits its instrument of ratification, or before the communication under Rule 71(3) EPC has been issued.

The second transitional measure enables applicants to request a delay in the EPO’s issuing of the decision to grant a European patent until immediately after the entry into force of the  UP system. Patentees may thus benefit from unitary protection and hence avoid country-by-country validation in the 17 participating countries. However, only requests filed after the date of Germany’s depositing of its instrument of ratification will be allowed. 

In respect of cases, where time limits for replying to ‘office actions’, i.e., communications under Article 94(3) EPC, or time limits under Rule 71(3) EPC, are already running, applicants who wish to benefit from unitary protection may consider not lodging early replies with the EPO. Rather, applicants may wish to benefit from the full reply periods available in order to increase their chances of being able to benefit from the transitional measures.

 

 

Jakob Pade Frederiksen

Partner, Inspicos P/S

E: jpf@inspicos.com

 

more from across site and ros bottom lb

More from across our site

In the first of a two-part UPC special, lawyers at A&O Shearman explain what you need to know about changes of procedural language and security for costs
Lawyers in the US and Europe reveal the work they focus on, how they stay one step ahead of creative counterfeiters, and why reputation matters
Abion said the appointment of Silvia Asioli and the launch of its Milan office will expand its market position in southern Europe
UK firms who have hired litigation and transactional lawyers reveal how they work together and the lessons have they learned
Jonah Mitchell tells us why he would have liked to have tried his hand at being a firefighter or chef
Noemi Parrotta, chair of the European subcommittee within INTA’s International Amicus Committee, explains why we might not have heard the last of the morality debate
Counsel say the USPTO's examples of AI patentability should make their lives easier and help point clients in the right direction
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Ehsun Forghany says he was impressed by the firm's focus on fashion and IP as well as the expertise of chairman Anthony Lupo
Counsel at medical device companies say the unitary patent, AI and terminal disclaimers are major areas of concern
Gift this article